Authors TNM stage of NSCLC Design of study Patients (
)
Intervention Measurements PFS, OS, MST, and TTP (m) Results/conclusion Treatment group Control group Treatment group Control group Liu et al., 2009 [44 ] Nonoperatable IIIA-IV RCT 31 31 Feitai Capsule — FACT-L, KPS, clinical symptoms — Feitai Capsule can improve the QOL.Chai et al., 2011 [45 ] IIIB-IV RCT 32 32 Xiaoji Yin — MST, PFS PFS: 5.1 versus 2.5 (
)
) Xiaoji Yin can prolong the MST and PFS.Jiang et al., 2011 [46 ] IIIB-IV RCT 25 25 Comprehensive TCM therapy Gemcitabine/P TTP, QOL(EORTC QLQ-LC43) TTP: 2.9 versus 2.13 (
) The TCM comprehensive regimen had equivalent efficacy on TTP but better QOL when compared with single-agent chemotherapy. Xi et al., 2011 [47 ] III-IV RCT 44 34 Hechan Pian — PFS, clinical symptoms median PFS: 5.67 versus 4.12 (
) Hechan Pian can prolong the median PFS and improve the clinical symptoms.Zeng et al., 2013 [48 ] IV RCT 34 35 Shenyi Capsule — Medin PFS, KPS, immune function (T-lymphocyte subtypes) median PFS: 6.5 versus 6.2 (
) Shenyi Capsule can improve the QOL and immune function which helps more patients to accept second-line chemotherapy.
Yang 2013 [49 ] III-IV RCT 40 40 Fuzheng Xiaoji Yin — PFS PFS: 7.5 versus 4.8 (
) Fuzheng Xiaoji Yin can prolong the PFS.Liang and Zhang 2013 [50 ] IIIB-IV RCT 38 36 Rongyan Capsule — MST, PFS PFS: 4.8 versus 2.37 (
)
) Rongyan Capsule can prolong the MST and PFS.Wang et al., 2013 [51 ] IV RCT 39 37 TCM therapy based on syndrome differentiation — PFS, QOL(EORTC-QLQ-C30), clinical symptoms PFS: 7.2 versus 4.4 (
) TCM therapy based on syndrome differentiation can improve the QOL, clinical symptoms and prolong the PFS. Wu et al., 2014 [52 ] IIIB-IV Nonrandomized controlled trial 20 20 Shenyi Capsule — DCR, PFS, OS PFS: 4.35 versus 2.67 (
)
) Shenyi Capsule can prolong the PFS and OS and improve the DCR.
